Search This Blog

Tuesday, April 30, 2024

Quest Adds Blood Biomarker Test to Assess Risk and Help Aid Diagnosis of Alzheimer's

 Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.

The test is the latest addition to the AD-Detect™ portfolio of blood tests for assessing the risk of Alzheimer's Disease, which also includes testing for an array of AD biomarkers, including p-tau181 and amyloid beta (AB) proteins, as well as Apolipoprotein E (ApoE) isoform and plasma testing, for patients with cognitive impairment. With a physician's test order, patients may provide a blood draw for testing from any of Quest's 2,000 patient service centers in the United States. The test is expected to be available for ordering on April 26, 2024.

Quest Diagnostics continually seeks to expand access for patients and providers to innovations in the field of dementia, including AD, through advanced diagnostic solutions. The addition of p-tau217 to Quest's existing portfolio of neurology testing supports a comprehensive offering, including not only the groundbreaking use of blood tests to evaluate risk of AD, but also cerebrospinal fluid (CSF) tests to help providers assess amyloid beta 42, tau and ApoE genetic risk status.

https://newsroom.questdiagnostics.com/2024-04-22-Quest-Diagnostics-Adds-p-tau217-Blood-Biomarker-Testing-to-Suite-of-Services-Designed-to-Assess-Risk-and-Help-Aid-Diagnosis-of-Alzheimers-Disease

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.